GENOR BIOPHARMA DL-00002 (67N0) — Net Asset Quality Index
GENOR BIOPHARMA DL-00002 (67N0) has a Net Asset Quality Index of 82.9% as of June 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €1.32 Billion minus total liabilities of €226.09 Million yields net assets of €1.10 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See GENOR BIOPHARMA DL-00002 working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Quality Index
Net Assets
Total Assets
Total Liabilities
GENOR BIOPHARMA DL-00002 Net Asset Quality Index Over Time (2021–2024)
This chart shows how GENOR BIOPHARMA DL-00002's Net Asset Quality Index has evolved across 4 annual periods from 2021 to 2024. As of June 2025, the index stands at 82.9%, representing net assets of €1.10 Billion against total assets of €1.32 Billion EUR. Explore GENOR BIOPHARMA DL-00002 cash flow conversion to assess how effectively this company generates cash.
Annual Net Asset Quality Index for GENOR BIOPHARMA DL-00002 (2021–2024)
The table below presents the year-by-year Net Asset Quality Index for GENOR BIOPHARMA DL-00002 from 2021 to 2024, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 67N0 market cap overview.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 89.3% | €1.15 Billion | €1.29 Billion | €138.05 Million | ▲ +7.0 pp |
| 2023 | 82.3% | €1.19 Billion | €1.45 Billion | €256.18 Million | ▼ -3.1 pp |
| 2022 | 85.3% | €1.81 Billion | €2.12 Billion | €309.87 Million | ▼ -1.7 pp |
| 2021 | 87.1% | €2.49 Billion | €2.86 Billion | €369.73 Million | — |